Related trials
JUPITER, 2008 - rosuvastatin vs placebo
Song, 2008 - vs
SAGE, 2007 - atorvastatin high dose vs pravastatin
METEOR, 2007 - rosuvastatin vs placebo
CORONA, 2007 - rosuvastatin vs placebo
Chello et al., 2006 - preoperative atorvastatin vs placebo
ASPEN, 2006 - atorvastatin vs placebo
SPARCL, 2006 - atorvastatin vs placebo
Patti et al., 2006 - preoperative atorvastatin vs placebo
MEGA, 2006 - pravastatin vs control
IDEAL, 2005 - atorvastatin high dose vs simvastatin
Vascular basis, 2005 - atorvastatin high dose vs lovastatin
TNT, 2005 - atorvastatin high dose vs atorvastatin
PACT, 2004 - pravastatin vs placebo
A to Z, 2004 - simvastatin vs placebo
ESTABLISH, 2004 - atorvastatin vs usual care
REVERSAL, 2004 - atorvastatin high dose vs pravastatin
HPS (sub groups), 2004 - simvastatin vs placebo
CARDS, 2004 - atorvastatin vs placebo
PACT, 2004 - pravastatin vs placebo
ASCOT, 2003 - atorvastatin vs placebo
LIPS (sub groups), 2002 - fluvastatin vs placebo
ALLHAT, 2002 - pravastatin vs usual care
PTT, 2002 - pravastatin vs usual care
PROSPER, 2002 - pravastatin vs placebo
See also:
All CABG surgery clinical trials
All clinical trials of cholesterol lowering intervention
All clinical trials of preoperative atorvastatin
|
|
Treatments
Studied treatment |
preoperative atorvastatin 40 mg/d, starting 7 days before operation
|
Control treatment |
placebo
|
Patients
Patients |
patients undergoing elective cardiac surgery with cardiopulmonary bypass, without previous statin treatment or history of AF |
Method and design
Randomized effectives |
101 / 99 (studied vs. control) |
Blinding |
double blind |
Follow-up duration |
30 days |
Results
Endpoint
Studied treat. n/N
Control treat. n/N
Graph
RR [95% CI]
atrial fibrillation
35 / 101
56 / 99
0,61 [0,45;0,84]
myocardial infarction (fatal and non fatal)
3 / 101
3 / 99
classic
0,98 [0,20;4,74]
All cause death
2 / 101
2 / 99
classic
0,98 [0,14;6,82]
0
2
1.0
Relative risks
|
Endpoint |
Events (%) |
Relative Risk |
95% CI |
Endpoint definition in the trial |
Ref |
Studied treat. |
Control treat. |
atrial fibrillation
|
35 / 101 (34,7%) |
56 / 99 (56,6%) |
0,61 |
[0,45;0,84] |
|
|
myocardial infarction (fatal and non fatal)
|
3 / 101 (3,0%) |
3 / 99 (3,0%) |
0,98 |
[0,20;4,74] |
|
|
All cause death
|
2 / 101 (2,0%) |
2 / 99 (2,0%) |
0,98 |
[0,14;6,82] |
|
|
The primary endpoint (if exists) appears in blod characters
|
Reference(s) used for data extraction:
0:
|
Endpoint |
studied treat. |
control treat. |
mean diff |
Absolute risk reduction (for a follow-up of 30 days)
|
Endpoint |
Events rate |
Absolute risk reduction (ARR) |
Studied treat. |
Control treat. |
atrial fibrillation |
34,65% |
56,57% |
-21,91%
|
myocardial infarction (fatal and non fatal) |
2,97% |
3,03% |
-0,06%
|
All cause death |
1,98% |
2,02% |
-0,04%
|
Meta-analysis of all similar trials:
cholesterol lowering intervention in CABG surgery for preoperative statins
Reference(s)
TrialResults-center ID |
TRC7246
|
Trials register # |
NA
|
-
Patti G, Chello M, Candura D, Pasceri V, D'Ambrosio A, Covino E, Di Sciascio G.
Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study..
Circulation 2006;114:1455-61
Pubmed
|
Hubmed
| Fulltext
|